Please use this identifier to cite or link to this item:
doi:10.22028/D291-35779
Title: | Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration |
Author(s): | Abdin, Alaa Din Mohamed, Asem Munteanu, Cristian Weinstein, Isabel Langenbucher, Achim Seitz, Berthold Suffo, Shady |
Language: | English |
Title: | International Journal of Retina and Vitreous |
Volume: | 7 |
Issue: | 1 |
Publisher/Platform: | BMC |
Year of Publication: | 2021 |
Free key words: | Neovascular age-related macular degeneration Afibercept Treat and extend Fixed protocol |
DDC notations: | 610 Medicine and health |
Publikation type: | Journal Article |
Abstract: | Background To assess the morphological and functional outcome of intravitreal aflibercept following the treat and extend protocol compared to the fixed protocol for treatment of eyes with neovascular age-related macular degeneration. Methods This retrospective study included 126 eyes of 113 patients with primary onset neovascular age-related macular degeneration who were followed for 12 months. All eyes were treated with 2 mg/0.05 mL aflibercept. All eyes received an upload with three monthly aflibercept injections. We subsequently studied two groups of eyes. For group 1, 54 eyes were treated following the treat and extend protocol. For group 2, 72 eyes were treated following the fixed protocol (fixed 2-monthly interval). Main outcome measures included: best corrected visual acuity (BCVA), central macular thickness (CMT) and number of injections. Results BCVA (logMAR) in group 1 vs group 2 was (0.61 ± 0.3 vs 0.72 ± 0.3, p = 0.09) before treatment and (0.48 ± 0.3 vs 0.51 ± 0.3, p = 0.6) after one year of treatment. CMT in group 1 vs group 2 was (371 ± 101 μm vs 393 ± 116 μm, p = 0.5) before treatment and (284 ± 60 μm vs 290 ± 67 μm, p = 0.1) after one year of treatment. Number of injections/eye in group 1 vs group 2 was (8.5 ± 2.2 vs 7.0 ± 0, p < 0.001). Conclusions Significant differences regarding BCVA and central macular thickness were not found between both treatment protocols during the first year of treatment using aflibercept. However, a significantly higher number of injections was needed for eyes in the treat and extend group during the first year of treatment. This might suggest that aflibercept should better not be extended past an 8 weeks interval during the first year of treatment. Study registration This study was approved by the Ethics Committee of the Medical Association of Saarland, Germany (Nr. 123/20, Date: 16.06.2020). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. |
DOI of the first publication: | 10.1186/s40942-021-00349-x |
Link to this record: | urn:nbn:de:bsz:291--ds-357798 hdl:20.500.11880/32624 http://dx.doi.org/10.22028/D291-35779 |
ISSN: | 2056-9920 |
Date of registration: | 17-Mar-2022 |
Faculty: | M - Medizinische Fakultät |
Department: | M - Augenheilkunde |
Professorship: | M - Univ.-Prof. Dr. Dipl.-Ing. Achim Langenbucher M - Prof. Dr. Berthold Seitz |
Collections: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Files for this record:
File | Description | Size | Format | |
---|---|---|---|---|
Abdin2021_Article_IntravitrealAfliberceptFollowi.pdf | 941,31 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License